ImaginAb, Duke-NUS Graduate Medical School, National Research Foundation cancer, endocrine/metabolic news

The partners launched joint laboratory Imaging Biomarker Development Lab to develop in vivo molecular imaging agents for cardiovascular and metabolic disease and cancer. The facilities, which will also research agents for stem cell biology, neurobiology and immunology will be used to support ImaginAb's R&D and will be accessible to industry and academic collaborators. Duke-NUS and ImaginAb retain development and commercialization rights to their individual agents but will have joint ownership of any IP that is jointly developed. The partners and the National Research Foundation jointly committed $15 million to the lab. ...